INKT MiNK Therapeutics, Inc.
Company Updates ·
MiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury.
MiNK reported first quarter 2026 results and said cash and cash equivalents were approximately $9.5 million at March 31, 2026. Preliminary data from the trial are expected in the second half of 2026.
The note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $5.8 million | $6.3 million |
| Net income (loss) | -$12.5 million | -$10.8 million |
| Cash from operations | -$5.9 million | -$9.6 million |
| Cash and equivalents | $13.4 million | $4.6 million |
MiNK Therapeutics, Inc. trades under the ticker INKT on NASDAQ.
MiNK Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6Q40.
The SEC Central Index Key (CIK) for MiNK Therapeutics, Inc. is 1840229. Its filings are on SEC EDGAR.
5,103,002 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13.
Our directory records MiNK Therapeutics, Inc. under United States.
Our directory classifies MiNK Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MiNK Therapeutics, Inc. is US6036932019.
aibio.space lists MiNK Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
MiNK Therapeutics, Inc. reported a net loss of $12.5 million for the fiscal year ended Dec 31, 2025, and used $5.9 million of cash in operations, per its annual report to the SEC.
$5.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
$8.8 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on MiNK Therapeutics, dated Aug 13, 2026: "MiNK reports second quarter 2026 results and early trial observations". MiNK said its cash and cash equivalents were $8.8 million as of June 30, 2026, and its second quarter net loss was $3.1 million. The company also reported Day 28 observations from its randomized Phase 2 trial in acute lung injury. Source.
We do not publish live share prices. In its annual report, MiNK Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $10.9 million as of Jun 30, 2025.
SEC records list MiNK Therapeutics, Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio